

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (EF-26) LISOCABTAGENE MARALEUCEL

PRONUNCIATION lis" oh kab' ta jeen mar" a loo' sel

THERAPEUTIC CLAIM Antineoplastic

DESCRIPTION

Autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (CAR; comprised of an FMC63 monoclonal antibody-derived single chain variable fragment (scFv), IgG-derived spacer, CD28 transmembrane domain, CD137 [4-1BB] costimulatory domain, and CD3 zeta signaling domain) and a truncated epidermal growth factor receptor (EGFRt).

TRADEMARK None as yet

SPONSOR Juno Therapeutics, Inc.

CODE DESIGNATION JCAR017

UNII 7K2YOJ14X0

WHO NUMBER 10805

SCS